In the treatment naive setting, we found that the de-novo model best-described the dynamics of tumours under gefitinib treatment, in two independent studies with different patient EGFR mutation selection criteria, IPASS (unselected Asian population) and IFUM (EGFR mutation positive Caucasian population). Here, EGFR is linked to neoplasm.